Expanded Access for IMMU-132
Sponsor
Gilead Sciences (Industry)
Overall Status
Approved for marketing
CT.gov ID
NCT04320693
Collaborator
(none)
Study Details
Study Description
Brief Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Study Type:
Expanded Access
Official Title:
Expanded Access for IMMU-132
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Gilead Sciences
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT04320693
Other Study ID Numbers:
- IMMU-132
First Posted:
Mar 25, 2020
Last Update Posted:
Aug 19, 2021
Last Verified:
Apr 1, 2020
Additional relevant MeSH terms: